Table 3.
Starting eGFR | Hazard ratio for ESRD | eGFR decline per year | Outcome
|
|||
---|---|---|---|---|---|---|
Life-years | QALYs per subject | Time to ESRD (y) | Number per 1,000 subjects reaching ESRD | |||
60 | 1.0 | 4.6 | 15.2 | 13.0 | 10.3 | 100 |
0.9 | 4.6 | 15.2 | 13.0 | 10.3 | 84 | |
0.8 | 4.6 | 15.2 | 13.0 | 10.4 | 68 | |
0.7 | 4.5 | 15.3 | 13.0 | 10.4 | 54 | |
52.5 | 1.0 | 4.6 | 14.8 | 12.6 | 10.2 | 148 |
0.9 | 4.5 | 14.8 | 12.6 | 10.2 | 126 | |
0.8 | 4.5 | 14.8 | 12.6 | 10.3 | 105 | |
0.7 | 4.5 | 14.8 | 12.6 | 10.3 | 84 | |
37.5 | 1.0 | 4.2 | 13.3 | 11.2 | 9.4 | 353 |
0.9 | 4.2 | 13.4 | 11.3 | 9.6 | 314 | |
0.8 | 4.2 | 13.4 | 11.4 | 9.8 | 273 | |
0.7 | 4.2 | 13.5 | 11.4 | 9.9 | 230 | |
22.5 | 1.0 | 3.1 | 11.3 | 9.3 | 7.7 | 677 |
0.9 | 3.1 | 11.6 | 9.6 | 8.1 | 630 | |
0.8 | 3.1 | 11.8 | 9.8 | 8.6 | 575 | |
0.7 | 3.2 | 12.0 | 10.0 | 9.0 | 509 |
Abbreviations: QALY, quality-adjusted life-year; ESRD, end-stage renal disease; y, years.